# Phase 2 anemia trials recruiting: 95 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 95 trials in phase 2 for anemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 anemia trials: 95 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/anemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 95
- Recruiting or not yet: 95
- Read on: November 19, 2026

## Trials

The 25 newest of 95, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07896928 | Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | MDS, Myelodysplastic Syndrome MDS, Myelodysplastic Syndrome (MDS), Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896928) |
| October 21, 2026 | NCT07885982 | Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT | Anhui Provincial Hospital | Phase 2 | Not yet recruiting | Aplastic Anaemia | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885982) |
| August 6, 2026 | NCT07750574 | Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Not yet recruiting | Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750574) |
| July 31, 2026 | NCT07738510 | A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell... | Halia Therapeutics, Inc. | Phase 2 | Not yet recruiting | Myelodysplastic Syndromes, Anemia | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738510) |
| July 24, 2026 | NCT07725497 | A Study of Luspatercept in People With Anemia | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Anemia, Chronic Kidney Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725497) |
| July 20, 2026 | NCT07715318 | Efficacy and Safety of Spironolactone in Pediatric Hemodialysis Patients With Anemia. | Ain Shams University | Phase 2 | Not yet recruiting | Anemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715318) |
| July 13, 2026 | NCT07698080 | Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific... | Hematology department of the 920th hospital | Phase 2 | Not yet recruiting | Leukemia, Lymphoma, Thalassemia, Aplastic Anemia, Myelodysplastic Syndromes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698080) |
| June 1, 2026 | NCT07616154 | Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | St. Jude Children's Research Hospital | Phase 2 | Recruiting | Sickle Cell Disease | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616154) |
| May 26, 2026 | NCT07607418 | Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS | Ruijin Hospital | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607418) |
| May 22, 2026 | NCT07603557 | Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 2 | Not yet recruiting | Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603557) |
| May 7, 2026 | NCT07572084 | Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | Aplastic Anemia | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572084) |
| April 30, 2026 | NCT07558434 | CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558434) |
| April 8, 2026 | NCT07516847 | Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Myelodysplastic Syndromes (MDS), Anemia | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516847) |
| March 30, 2026 | NCT07499102 | CK0801 for Treatment of Aplastic Anemia | Cellenkos, Inc. | Phase 2 | Not yet recruiting | Aplastic Anemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499102) |
| March 6, 2026 | NCT07453368 | Orelabrutinib in the Treatment of Relapsed/Refractory AIHA | Peking Union Medical College Hospital | Phase 2 | Recruiting | Autoimmune Hemolytic Anemia (AIHA) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453368) |
| March 4, 2026 | NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | Sponsor not shown (see the record) | Phase 2 | Recruiting | Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447817) |
| February 10, 2026 | NCT07400341 | Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400341) |
| January 27, 2026 | NCT07369024 | Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults | Sponsor not shown (see the record) | Phase 2 | Recruiting | Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369024) |
| January 27, 2026 | NCT07368972 | Study of DISC-0974-201 in Participants With IBD and Anemia | Disc Medicine, Inc | Phase 2 | Recruiting | Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368972) |
| December 15, 2025 | NCT07282210 | Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype | Biossil Inc. | Phase 2 | Recruiting | Sickle Cell Disease, Sickle Cell Anaemia, Sickle Cell Anemia | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282210) |
| November 25, 2025 | NCT07249346 | Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249346) |
| November 4, 2025 | NCT07224360 | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) | CSL Behring | Phase 2 | Recruiting | Sickle Cell Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224360) |
| October 9, 2025 | NCT07214064 | Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation | University Hospital Tuebingen | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia), MDS/AML, MDS (Myelodysplastic Syndrome) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214064) |
| September 24, 2025 | NCT07190261 | A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Autoimmune Hemolytic Anemia | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190261) |
| September 16, 2025 | NCT07175051 | Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin | University of Illinois Chicago | Phase 2 | Recruiting | Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175051) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Masonic Cancer Center, University of Minnesota | 5 |
| M.D. Anderson Cancer Center | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Peking Union Medical College Hospital | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| St. Jude Children's Research Hospital | 3 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| University of Illinois Chicago | 2 |
| [CSL Behring](https://specstream.ai/data/clinical-trials/company/csl-behring) | 2 |
| Forma Therapeutics, Inc. | 2 |
| Hematology department of the 920th hospital | 2 |
| Fox Chase Cancer Center | 1 |
| The University of Hong Kong | 1 |
| Theravia | 1 |
| Cellenkos, Inc. | 1 |
| Weill Medical College of Cornell University | 1 |
| Medical College of Wisconsin | 1 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| [Chengdu Zenitar Biomedical Technology Co., Ltd](https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd) | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| National Cancer Institute (NCI) | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| Ain Shams University | 1 |
| [Apellis Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/apellis-pharmaceuticals-inc) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 56 |
| China | 10 |
| France | 8 |
| United Kingdom | 6 |
| Italy | 5 |
| Germany | 5 |
| Canada | 4 |
| Denmark | 3 |
| Turkey (Türkiye) | 3 |
| Spain | 2 |
| Netherlands | 2 |
| Nigeria | 2 |
| Hong Kong | 1 |
| French Guiana | 1 |
| Australia | 1 |
| Brazil | 1 |
| South Korea | 1 |
| Czechia | 1 |
| Malaysia | 1 |
| Serbia | 1 |
| Thailand | 1 |
| Belgium | 1 |
| Austria | 1 |
| India | 1 |
| Oman | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drywall contractors in the United States](https://specstream.ai/data/businesses/drywall-contractors/united-states)
- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Uzbek restaurants in the United States](https://specstream.ai/data/businesses/uzbek-restaurants/united-states)
- [Public relations firms in the United States](https://specstream.ai/data/businesses/public-relations-firms/united-states)
- [Masonry and concrete contractors in the United States](https://specstream.ai/data/businesses/masonry-and-concrete-contractors/united-states)
- [Furniture manufacturers in the United States](https://specstream.ai/data/businesses/furniture-manufacturers/united-states)
